IQVIA Holdings Inc. $IQV Shares Acquired by Diversified Trust Co.

Diversified Trust Co. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 14.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,876 shares of the medical research company’s stock after buying an additional 6,297 shares during the period. Diversified Trust Co.’s holdings in IQVIA were worth $11,017,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its holdings in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Westside Investment Management Inc. increased its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in IQVIA in the 3rd quarter valued at about $30,000. Atlantic Union Bankshares Corp acquired a new position in IQVIA during the 3rd quarter valued at about $36,000. Finally, Asset Dedication LLC grew its position in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Citigroup lowered their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Morgan Stanley set a $240.00 target price on IQVIA in a research note on Wednesday, February 11th. Finally, Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $229.13.

IQVIA Trading Up 0.6%

IQVIA stock opened at $167.14 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market capitalization of $28.36 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.40. The firm has a 50 day simple moving average of $192.66 and a 200-day simple moving average of $206.07.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.